Biotech struggles as 2Q opens
Biotech began the second quarter on a sour note, closing the week in worse shape than the broader market. The
On Friday, the BTK, NBI, XBI and BioCentury 100 each shed about 3% as a Phase III miss by
The Dow, NASDAQ and S&P500 each slid about 2% on the final trading day of the week.
This week's roller-coaster ride follows a volatile March that wiped out first quarter equity gains across the board; however, a dozen investors who spoke to BioCentury for its 2Q18 Financial Markets Preview are reveling under conditions they say favor stock picking (see BioCentury, April 6).
(C) 2018 M2 COMMUNICATIONS, source